-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
October 1, 2020 /--- researchers at the University of Sheffield recently published their assessment of a new, rapid COVID-19 test technology.
LamPORE is a new diagnostic platform for detecting SARS-CoV-2RNA, combining ring-mediated isomodes with nanopore sequencing, with the potential to analyze thousands of samples per day on one instrument.
, although preliminary, the results suggest that LamPORE is highly sensitive to diagnosis, which may mean that larger detection scales may be available in the future to help control the SARS-CoV-2 pandemic.
(Photo credit: www.pixabay.com) a collaboration between the University of Sheffield and Public Health England Porton Down (PHE), Sheffield Teaching Hospitals NHS Foundation Trust and colleagues at Oxford University assessed LamPORE's performance against RT-PCR.
team used RNA extracted from two samples.
positive clinical specimens were mainly from patients with symptomatic infections, of which LamPORE had a diagnostic sensitivity of 99.1% (i.e. 226 out of 228 RT-PCR-positive samples).
in negative clinical specimens, including 153 other respiratory pathogens detected, LamPORE was diagnosed with a specificity of 99.6% (i.e. 278 out of 279 were negative RT-PCR negative).
overall, 1.4% of the samples produced uncertain results during the first test, and the repeatability of repeated LamPORE tests on the same RNA extract was 96.8%.
results show that LamPORE has the performance of SARS-CoV-2 infection in patients with diagnostic symptoms similar to RT-PCR.
Suchhan de Silva, of the Department of Infection, Immunology and Cardiovascular Disease at the University of Sheffield, said: "These preliminary but promising data suggest that LamPORE has the potential to expand the type and scale of SARS-CoV-2 testing.
, from Porton Down Public Health England, said: "Our early data suggest that LamPORE is a reliable alternative to pcR-based conventional diagnostic methods, which have the potential to provide further high-volume detection capabilities.
.com Source: Evaluation of rapid tests for COVID-19 show high levels of diagnostics.
